The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting edge data to practising healthcare professionals. Our aim is to provide clinically relevant information in order to enhance the caregivers' ability to provide optimal care for their gastrointestinal (GI) cancer patients. We will offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, will function as a hub of information for healthcare professionals. 

Our initial focus for Advances in Gastrointestinal Cancer will centre on gastric cancer, with future expansion to all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.

ESMO 2016 Congress highlights

Article of the month

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced or recurrent gastric cancer (JFMC45-1102)

Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al.
Int J Cancer 2016 Aug 13. [Epub ahead of print]

Selected and commented by Professor David Cunningham:

In this study, Japanese investigators examined the efficacy of 2nd line trastuzumab plus paclitaxel in gastric cancer patients with HER2 positive tumours. Of note, although patients had received prior chemotherapy, they were trastuzumab naïve. The objective radiological response rate was 37% and progression free and overall survival in this trial were survival were 5.1 (95% CI 3.8–6.5) and 17.1 (95% CI 13.5–18.6) months, respectively. These results are encouraging but there are several important caveats which must be considered...

Latest Articles


Professor David Cunningham

Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research

Professor Florian Lordick

University Hospital Leipzig, Leipzig, Germany

Dr Ian Chau

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Dr James J. Lee

Division of Medical Oncology and Hematology, UPMC Cancer Centre, Pittsburgh, PA, USA

Dr Elizabeth Smyth

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Search this site

Search form


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content

  • ECC Symposium: The why, the which, and the how of targeting angiogenesis in GI malignancies

    Official Sponsored Satellite Symposium at European Cancer Congress 2015 - Monday 28 September 2015

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.


Upcoming events